SCHEMBL2174004

SCHEMBL2174004

Cc1cc(N)ccc1CN(C)C

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.48
SLC6A4 P31645 6/20 0.44
HTR2A P28223 1/20 0.44
PDE10A Q9Y233 1/20 0.43
CASP1 P29466 2/20 0.41
SLC6A2 P23975 4/20 0.41
MAPT P10636 3/20 0.40
KDM4E B2RXH2 2/20 0.40
MEN1 O00255 2/20 0.40
GAA P10253 2/20 0.40
THRB P10828 2/20 0.40
KMT2A Q03164 2/20 0.40
L3MBTL1 Q9Y468 2/20 0.40
CYP1A2 P05177 1/20 0.40
CYP2C19 P33261 1/20 0.40
POLB P06746 1/20 0.40
G6PD P11413 1/20 0.40
PABPC1 P11940 1/20 0.40
HKDC1 Q2TB90 1/20 0.40
TDP1 Q9NUW8 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2176041 0.85 ALDH1A1 (0.50) ALDH1A1SLC6A4HTR2APDE10ACASP1
Hydrochloric Acid SCHEMBL5913639 0.83 ALDH1A1 (0.48) ALDH1A1SLC6A4HTR2APDE10ACASP1
SCHEMBL1708813 0.78 SLC6A4 (0.50) ALDH1A1SLC6A4HTR2ACASP1SLC6A2
SCHEMBL11316837 0.78 PYCR1 (0.59) ALDH1A1SLC6A4HTR2ASLC6A2MAPT
SCHEMBL272096 0.78 ALDH1A1 (0.56) ALDH1A1PDE10ACASP1MAPTKDM4E
SCHEMBL29673045 0.78 ALDH1A1 (0.56) ALDH1A1PDE10ACASP1MAPTKDM4E
SCHEMBL865950 0.78 ALDH1A1 (0.56) ALDH1A1PDE10ACASP1MAPTKDM4E
SCHEMBL3197622 0.78 SLC6A4 (0.54) ALDH1A1SLC6A4HTR2ASLC6A2MAPT
SCHEMBL13159521 0.78 ADRA2B (0.44) ALDH1A1SLC6A4HTR2ASLC6A2MAPT
SCHEMBL2989381 0.78 SLC6A4 (0.43) ALDH1A1SLC6A4HTR2ASLC6A2MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230167110-A1 6-HETEROARYLOXY BENZIMIDAZOLES AND AZABENZIMIDAZOLES AS JAK2 INHIBITORS SCHRÖDINGER, INC. 2023-06-01 US disclosed
WO-2023069959-A1 COVALENT EGFR INHIBITORS AND METHODS OF USE THEREOF DANA-FARBER CANCER INSTITUTE, INC. (US) 2023-04-27 WO disclosed
WO-2011156775-A2 8-(2'-HETEROCYCYL)PYRIDO[2.3-D]PYRIMIDIN-7(8H)-ONES FOR THE TREATMENT OF CNS DISORDERS AFRAXIS, INC. (US) 2011-12-15 WO disclosed
US-7973164-B2 Quinoline derivatives ASTRAZENECA AB (SE) 2011-07-05 US disclosed
CN-101437811-A Quinoline derivatives ASTRAZENECA AB (SE) 2009-05-20 CN disclosed
US-20090076074-A1 QUINOLINE DERIVATIVES ASTRAZENECA AB (SE) 2009-03-19 US disclosed
EP-1994025-A1 QUINOLINE DERIVATIVES AstraZeneca AB (SE) 2008-11-26 EP disclosed
WO-2007099326-A1 QUINOLINE DERIVATIVES ASTRAZENECA AB (SE) 2007-09-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230167110-A1 6-HETEROARYLOXY BENZIMIDAZOLES AND AZABENZIMIDAZOLES AS JAK2 INHIBITORS JAK2, JAK3, STAT5B ALDH1A1 3735/4885SLC6A4 4557/4885HTR2A 1660/4885
US-20090076074-A1 QUINOLINE DERIVATIVES RECQL, NQO2, CCNA1 ALDH1A1 887/4885SLC6A4 1676/4885HTR2A 1721/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.